These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33238595)

  • 1. New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.
    Varì MR; Mannocchi G; Tittarelli R; Campanozzi LL; Nittari G; Feola A; Umani Ronchi F; Ricci G
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33238595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day.
    Andrews R; Jorge R; Christie R; Gallegos A
    Drug Test Anal; 2023 Apr; 15(4):378-387. PubMed ID: 36507715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complex and constantly evolving public health threat of new psychoactive substances in Italy: addressing the main functions of a national observatory of drugs.
    Graziano S; Zaami S; Tittarelli R; Pichini S; Sciotti M; Berretta P; Busardò FP; Marinelli E; Tini A; Scaravaggi G; Buscaglia E; Brambilla E; Cavallo M; Locatelli CA; Pacifici R; Varì MR
    Ann Ist Super Sanita; 2021; 57(2):144-150. PubMed ID: 34132212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring psychoactive substance use at six European festivals through wastewater and pooled urine analysis.
    Bijlsma L; Celma A; Castiglioni S; Salgueiro-González N; Bou-Iserte L; Baz-Lomba JA; Reid MJ; Dias MJ; Lopes A; Matias J; Pastor-Alcañiz L; Radonić J; Turk Sekulic M; Shine T; van Nuijs ALN; Hernandez F; Zuccato E
    Sci Total Environ; 2020 Jul; 725():138376. PubMed ID: 32298891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European dimension of cannabinoid-like products use.
    Surugiu ME; Mincă DG
    J Med Life; 2012 Feb; 5(1):79-81. PubMed ID: 22574091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances.
    Guillou C; Reniero F; Lobo Vicente J; Holland M; Kolar K; Chassaigne H; Tirendi S; Schepers H
    Curr Pharm Biotechnol; 2018; 19(2):91-98. PubMed ID: 29792142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The challenges for psychiatric care posed by synthetic drugs].
    Scherbaum N; Bonnet U
    Nervenarzt; 2024 Sep; 95(9):818-823. PubMed ID: 39186107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of synthetic substances in France and in Europe].
    Debruyne D; Monzon E; Perino J; Haramburu F; Daveluy A; Lazès-Charmetant A; Giraudon I
    Therapie; 2021; 76(3):221-228. PubMed ID: 32859404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Snapshot of narcotic drugs and psychoactive substances in Kuwait: analysis of illicit drugs use in Kuwait from 2015 to 2018.
    Al-Matrouk A; Al-Hasan M; Naqi H; Al-Abkal N; Mohammed H; Haider M; Al-Shammeri D; Bojbarah H
    BMC Public Health; 2021 Apr; 21(1):671. PubMed ID: 33827491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.
    Hohmann N; Mikus G; Czock D
    Dtsch Arztebl Int; 2014 Feb; 111(9):139-47. PubMed ID: 24661585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New psychoactive substances and their prevalence in the Czech Republic].
    Mravčík V; Běláčková V; Grohmannová K; Zábranský T
    Cas Lek Cesk; 2015; 154(5):216-21. PubMed ID: 26612328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic cathinones: an evolving class of new psychoactive substances.
    Gonçalves JL; Alves VL; Aguiar J; Teixeira HM; Câmara JS
    Crit Rev Toxicol; 2019 Aug; 49(7):549-566. PubMed ID: 31747318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug abuse monitoring: which pharmacoepidemiological resources at the European level?
    Lapeyre-Mestre M; Dupui M
    Therapie; 2015; 70(2):147-65. PubMed ID: 25858571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Growing Problem of New Psychoactive Substances (NPS).
    Madras BK
    Curr Top Behav Neurosci; 2017; 32():1-18. PubMed ID: 27571747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
    Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.